At Bethesda, Maryland, USA
Tergus Pharma CEO, Vijendra Nalamothu, PhD will be speaking on Impact of vehicle on performance and safety: usage of the early development data to de-risk clinical formulations
An International Workshop on De-Risking Strategies from Candidate Selection to Regulatory Approval
The workshop will address key issues and challenges in the evolving landscape of topical drug development. Practical and effective approaches to de-risk topical drug development of new drugs as well as generics will be covered including candidate selection, formulation issues, approaches for determination of PK/PD and paths through to marketing authorization.